Lakewood-Amedex Biotherapeutics debuts on Nasdaq as LABT, a clinical-stage biotech targeting antibiotic-resistant infections like MRSA and VRE with its Bisphosphocin class. Lead asset Nu-3 gel goes af

This wasn't a traditional IPO — it's a direct listing. No new capital raised at listing, with existing holders registering up to 4.7 million shares. Separately, the company sold 937,500 Series C Preferred shares for $7.5 million at a 20% discount. The pipeline is early. Nu-3 completed a first-in-human trial, with a Phase 2a safety/dose-response study planned before a placebo-controlled Phase 2b. No product candidate has been approved for commercial sale, and development risk remains high. Key risks: biopharma development is uncertain and candidates can fail on efficacy, safety, or regulatory delays. Commercial success also hinges on third-party payor coverage and reimbursement, which may be limited or face cost-cutting pressure. Bottom line: a micro-cap antimicrobial play riding the AMR policy tailwind, but it's pre-revenue, capital-light at listing, and years from any approval. The direct listing structure and preferred discount are worth a close look before chasing this one.

This wasn't a traditional IPO — it's a direct listing. No new capital raised at listing, with existing holders registering up to 4.7 million shares. Separately, the company sold 937,500 Series C Prefe